Company intelligence / Profile preview

Bazell Pharma AG

Allschwil, Switzerlandamzell.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Before acquisition, the company had two lead candidates that reached Phase 3 trials: AMZ001 for Osteoarthritis of the Knee and AMZ002 for Infantile Epileptic Disease. AMZ001 showed efficacy and safety in the relief of pain associated with osteoarthritis of the knee in a phase 2/3 trial published in August 2020[1][7].

Therapeutic areas: NeurologyRheumatology
Modalities: Small molecules (specifically diclofenac formulation)
Industry: Biotech

Drug pipeline

3 assets

diclofenac

Phase 3

Indications: Osteoarthritis of the knee

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Bazell Pharma AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bazell Pharma AG.

Explore the full profile